- Home
- NEGG vs IPHA Comparison
NEGG vs IPHA Comparison
Compare NEGG & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEGG
- IPHA
- Stock Information
- Founded
- NEGG 2001
- IPHA 1999
- Country
- NEGG United States
- IPHA France
- Employees
- NEGG N/A
- IPHA N/A
- Industry
- NEGG Other Specialty Stores
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- NEGG Consumer Discretionary
- IPHA Health Care
- Exchange
- NEGG Nasdaq
- IPHA Nasdaq
- Market Cap
- NEGG 122.3M
- IPHA 160.1M
- IPO Year
- NEGG 2010
- IPHA 2019
- Fundamental
- Price
- NEGG $46.34
- IPHA $2.18
- Analyst Decision
- NEGG
- IPHA Hold
- Analyst Count
- NEGG 0
- IPHA 2
- Target Price
- NEGG N/A
- IPHA $2.00
- AVG Volume (30 Days)
- NEGG 1.2M
- IPHA 16.8K
- Earning Date
- NEGG 12-01-2025
- IPHA 09-17-2025
- Dividend Yield
- NEGG N/A
- IPHA N/A
- EPS Growth
- NEGG N/A
- IPHA N/A
- EPS
- NEGG N/A
- IPHA N/A
- Revenue
- NEGG $1,313,127,000.00
- IPHA $14,839,695.00
- Revenue This Year
- NEGG N/A
- IPHA $50.89
- Revenue Next Year
- NEGG N/A
- IPHA N/A
- P/E Ratio
- NEGG N/A
- IPHA N/A
- Revenue Growth
- NEGG N/A
- IPHA N/A
- 52 Week Low
- NEGG $3.32
- IPHA $1.29
- 52 Week High
- NEGG $137.84
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- NEGG 47.90
- IPHA 59.91
- Support Level
- NEGG $44.63
- IPHA $1.95
- Resistance Level
- NEGG $52.44
- IPHA $2.10
- Average True Range (ATR)
- NEGG 4.50
- IPHA 0.07
- MACD
- NEGG 0.61
- IPHA 0.03
- Stochastic Oscillator
- NEGG 45.32
- IPHA 70.62
About NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products and provides certain third-party logistics services globally. Geographically, it operates in United States, Canada, and Rest of World.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.